Remedy completes end-of-phase 2 meeting with FDA on novel drug treatment for CNS-related edema
Remedy Pharmaceuticals CEO Sven Jacobson said: "Our End-of-Phase 2 meeting was a decisive milestone for the Company as we advance the clinical development of CIRARA.. "We are pleased
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.